<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased sympathetic tone is a consequence of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the role of <z:chebi fb="2" ids="33567">catecholamines</z:chebi> in ischemic damage is still unclear, in some experimental <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> models alpha2-adrenergic agonism has proved to be neuroprotective </plain></SENT>
<SENT sid="2" pm="."><plain>In the present work we have compared the effects of transient and permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) on the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, and, also, examined whether a selective alpha2-<z:chebi fb="0" ids="37886">adrenergic receptor agonist</z:chebi>, <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> (9 microg/kg or 15 microg/kg i.v.), is able to reduce ischemic damage after transient or permanent MCAO in rats </plain></SENT>
<SENT sid="3" pm="."><plain>Permanent MCAO led to a significantly larger <z:mpath ids='MPATH_124'>infarct</z:mpath> volume than transient occlusion (p &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>The rats receiving the higher dose of <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> were detectected to have smaller (statistically non-significant) <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in the cortex (30.9%) and in the striatum (20.3%) after transient occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>Additionally, <z:chebi fb="0" ids="4466">dexmedetomidine</z:chebi> caused significant variations in the physiological parameters </plain></SENT>
</text></document>